| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics
|
Hong, Enping
|
|
2019
|
141 |
C |
p. 3-22
|
article
|
| 2 |
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
|
Hutmacher, Cornelia
|
|
2019
|
141 |
C |
p. 67-91
|
article
|
| 3 |
CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs
|
Rahbarizadeh, F.
|
|
2019
|
141 |
C |
p. 41-46
|
article
|
| 4 |
Editorial Board
|
|
|
2019
|
141 |
C |
p. ii
|
article
|
| 5 |
Engineering lymphocytes with RNAi
|
Ramishetti, Srinivas
|
|
2019
|
141 |
C |
p. 55-66
|
article
|
| 6 |
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
|
Margolis, Naama
|
|
2019
|
141 |
C |
p. 104-124
|
article
|
| 7 |
Reprogramming the lymphocyte axis for advanced immunotherapy
|
Moghimi, S. Moein
|
|
2019
|
141 |
C |
p. 1-2
|
article
|
| 8 |
Synthetic T cell receptor-based lymphocytes for cancer therapy
|
Getts, Daniel
|
|
2019
|
141 |
C |
p. 47-54
|
article
|
| 9 |
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
|
Karnell, Jodi L.
|
|
2019
|
141 |
C |
p. 92-103
|
article
|
| 10 |
T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer
|
Eisenberg, Vasyl
|
|
2019
|
141 |
C |
p. 23-40
|
article
|
Journal description